Cargando…

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

Detalles Bibliográficos
Autores principales:	Duchmann, M, Braun, T, Micol, J-B, Platzbecker, U, Park, S, Pilorge, S, Beyne-Rauzy, O, Vey, N, Sébert, M, Gruson, B, Dumas, P-Y, Guieze, R, Chretien, M-L, Laribi, K, Chait, Y, Legros, L, Sahnes, L, Hirsch, P, Salanoubat, C, Solary, E, Fenaux, P, Itzykson, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518885/ https://www.ncbi.nlm.nih.gov/pubmed/28498370 http://dx.doi.org/10.1038/bcj.2017.41

Ejemplares similares

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
por: Moyo, Tamara K., et al.
Publicado: (2022)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Tracking chronic myelomonocytic leukaemia diversity at the single cell level
por: Solary, Eric
Publicado: (2020)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
por: Tarfi, Sihem, et al.
Publicado: (2018)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

A case of histoplasmosis in a patient with MDS/MPN-U
por: Rastogi, Pulkit, et al.
Publicado: (2016)

Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias
por: Duchmann, Matthieu, et al.
Publicado: (2021)

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
por: Merlevede, Jane, et al.
Publicado: (2016)

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
por: Akutagawa, Jon, et al.
Publicado: (2016)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia
por: Beke, Allan, et al.
Publicado: (2020)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
por: Jutzi, Jonas S., et al.
Publicado: (2015)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report
por: Bouchla, Anthi, et al.
Publicado: (2018)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study()
por: de Renzis, Benoit, et al.
Publicado: (2013)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
por: Spivak, Jerry L., et al.
Publicado: (2021)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
por: Patnaik, M M, et al.
Publicado: (2017)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

A knockout combination for MPN stem cells
por: Bywater, Megan, et al.
Publicado: (2020)

Chronic myeloid leukemia: a type of MPN
por: Samad, Muhammad Ammar, et al.
Publicado: (2022)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage
por: Cherniawsky, Hannah, et al.
Publicado: (2023)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bt7t33hudhr5fie4hhfe15da7c